PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Aflibercept in macular oedema after BRVO: No hint of added benefit

Dossier contained no suitable data, manufacturer itself claimed no added benefit

2015-06-23
(Press-News.org) Since February 2015, aflibercept (trade name Eylea) has been available also for patients with impaired vision due to macular oedema that follows blockage of branch veins of the central retinal vein (branch retinal vein occlusion, BRVO). The German Institute for Quality and Efficiency in Health Care (IQWiG) examined in a dossier assessment whether this drug offers an added benefit over the appropriate comparator therapy. Such an added benefit cannot be derived from the dossier because it contained no data relevant for the assessment.

Manufacturer considered only the comparison with ranibizumab to be adequate

The Federal Joint Committee (G-BA) had specified the drug ranibizumab or grid laser therapy as appropriate comparator therapy. The drug manufacturer accepted only ranibizumab, but not laser therapy.

There has been no study so far that has tested aflibercept against ranibizumab. One randomized controlled trial is available for the comparison with grid laser therapy (VIBRANT), but the study population of this study does not comply with the approval population, i. e. aflibercept was not used as recommended in the approval.

Apart from the fact that the VIBRANT study is unsuitable for the benefit assessment because of this, the manufacturer also did not use it because it rejected grid laser therapy as comparator therapy. As a consequence, the company claimed no added benefit for aflibercept.

Already fourth dossier assessment of the drug

In 2013 and 2014, IQWiG assessed aflibercept already three times for therapeutic indications in the eye according to the Act on the Reform of the Market for Medicinal Products (AMNOG). The researchers concluded in all three cases that no hint of added benefit can be derived from the dossiers. In these three therapeutic indications, however, the pharmaceutical company had claimed that its drug has an advantage in comparison with conventional treatments.

G-BA decides on the extent of added benefit

This dossier assessment is part of the early benefit assessment according to AMNOG supervised by the G-BA. After publication of the dossier assessment, the G-BA conducts a commenting procedure and makes a final decision on the extent of the added benefit.

INFORMATION:

An overview of the results of IQWiG's benefit assessment is given by a German-language executive summary. In addition, the website » http://www.gesundheitsinformation.de, published by IQWiG, provides easily understandable German-language Information.

More English-language information will be available soon (Sections 2.1 to 2.6 of the dossier assessment as well as subsequently published health information on » http://www.informedhealthonline.org). If you would like to be informed when these documents are available, please send an e-mail to » info@iqwig.de.



ELSE PRESS RELEASES FROM THIS DATE:

The pertussis pathogen -- New findings

2015-06-23
The worldwide spreading of the whooping cough, also known as pertussis, has substantially increased since 2010. Researchers from the Biozentrum, University of Basel, have investigated structure and function of an important membrane protein of the bacterium causing pertussis. They discovered that the protein structure differs from a previously postulated model. Their findings, published in "Nature Communications", provide a basis for new treatment approaches for the infection. Many tiny protein pores are found in the outer membrane of the pertussis pathogen, the bacterium ...

NIH study on atrial fibrillation published in New England Journal of Medicine

2015-06-23
TORONTO -- Alex C. Spyropoulos, M.D., system medical director of the Anticoagulation and Clinical Thrombosis Services at the North Shore-LIJ Health System is part of the steering committee that will discuss results of the BRIDGE study, a randomized trial on atrial fibrillation June 22 at The International Society on Thrombosis and Haemostasis (ISTH) 2015 Congress. The findings are published simultaneously in the June issue of New England Journal of Medicine. Atrial fibrillation is an irregular and often rapid heart rate that commonly causes poor blood flow to the body. ...

Nonphotosynthetic pigments could be biosignatures of life on other worlds

2015-06-23
To find life in the universe, it helps to know what it might look like. If there are organisms on other planets that do not rely wholly on photosynthesis -- as some on Earth do not -- how might those worlds appear from light-years away? That's among the questions University of Washington doctoral student Edward Schwieterman and astronomer Victoria Meadows of the UW-based, interdisciplinary Virtual Planetary Laboratory sought to answer in research published in May in the journal Astrobiology. Using computer simulations, the researchers found that if organisms with nonphotosynthetic ...

Adolescents uncertain about risks of marijuana, e-cigarettes, Stanford study finds

2015-06-23
Teenagers are very familiar with the risks of smoking cigarettes, but are much less sure whether marijuana or e-cigarettes are harmful, according to a new study by researchers at the Stanford University School of Medicine. While adolescents get clear messages from their families, teachers, peers and the media about the harms of smoking cigarettes, they receive conflicting or sparse information about the harms of marijuana and e-cigarettes, the study showed. The findings will be published online June 23 in the Journal of Adolescent Health. "Kids were really good at ...

Stanford research sheds light on how neurons control muscle movement

2015-06-23
Stanford University researchers studying how the brain controls movement in people with paralysis, related to their diagnosis of Lou Gehrig's disease, have found that groups of neurons work together, firing in complex rhythms to signal muscles about when and where to move. "We hope to apply these findings to create prosthetic devices, such as robotic arms, that better understand and respond to a person's thoughts," said Jaimie Henderson, MD, professor of neurosurgery. A paper describing the study will be published online June 23 in eLife. Henderson, who holds the ...

'Smarter' ordering of breast biomarker tests could save millions in health care dollars

2015-06-23
A review of medical records for almost 200 patients with breast cancer suggests that more selective use of biomarker testing for such patients has the potential to save millions of dollars in health care spending without compromising care, according to Johns Hopkins researchers. Specifically, waiting to perform these tests until a patient has a full excisional biopsy instead of "reflexively" or automatically testing for them on initial small "core" biopsies could save as much as $117 million, according to a report on the study published in the July issue of The American ...

Cocktail of chemicals trigger cancer -- global taskforce calls for research into how everyday chemicals in our environment cause cancer

2015-06-23
A global taskforce of 174 scientists from leading research centres across 28 countries studied the link between mixtures of commonly encountered chemicals and the development of cancer. The study selected 85 chemicals not considered carcinogenic to humans and found 50 supported key cancer-related mechanisms at exposures found in the environment today. Longstanding concerns about the combined and additive effects of everyday chemicals prompted the organisation Getting To Know Cancer led by Lowe Leroy from Halifax Nova Scotia, to put the team together - pitching what is ...

Cockroach-inspired robot uses body streamlining to negotiate obstacles

Cockroach-inspired robot uses body streamlining to negotiate obstacles
2015-06-23
Researchers at University of California, Berkeley have taken inspiration from the cockroach to create a robot that can use its body shape to manoeuvre through a densely cluttered environment. Fitted with the characteristic rounded shell of the discoid cockroach, the running robot can perform a roll manoeuvre to slip through gaps between grass-like vertical beam obstacles without the need for additional sensors or motors. It is hoped the robot can inspire the design of future terrestrial robots to use in a wide variety of scenarios, from monitoring the environment to ...

Gut microbe may be key to metabolic health and leanness in overweight/obesity

2015-06-23
The gut microbe Akkermansia muciniphila may hold the key to better metabolic health and healthier body fat distribution in people who are overweight or obese, reveals a small study published online in the journal Gut. The microbe seems to be linked to lower levels of fasting blood glucose and fats--key factors involved in the development of diabetes and heart disease--and healthier distribution of body fat, the findings indicate. In healthy people A. muciniphila makes up around 3-5% of the gut's bacterial ecosystem and is associated with a diet rich in insoluble fibre. The ...

Squatting in 'skinny' jeans can damage nerve and muscle fibers in legs and feet

2015-06-23
Squatting in 'skinny' jeans for a protracted period of time can damage muscle and nerve fibres in the legs, making it difficult to walk, reveals a case study published online in the Journal of Neurology Neurosurgery & Psychiatry. Doctors describe a case of a 35 year old woman who arrived at hospital with severe weakness in both her ankles. The previous day she had been helping a relative move house, and had spent many hours squatting while emptying cupboards. She had been wearing tight 'skinny' jeans and recalled that these had felt increasingly tight and uncomfortable ...

LAST 30 PRESS RELEASES:

MSU researchers find trees acclimate to changing temperatures

World's first visual grading system developed to combat microplastic fashion pollution

Teenage truancy rates rise in English-speaking countries

Cholesterol is not the only lipid involved in trans fat-driven cardiovascular disease

Study: How can low-dose ketamine, a ‘lifesaving’ drug for major depression, alleviate symptoms within hours? UB research reveals how

New nasal vaccine shows promise in curbing whooping cough spread

Smarter blood tests from MSU researchers deliver faster diagnoses, improved outcomes

Q&A: A new medical AI model can help spot systemic disease by looking at a range of image types

For low-risk pregnancies, planned home births just as safe as birth center births, study shows

Leaner large language models could enable efficient local use on phones and laptops

‘Map of Life’ team wins $2 million prize for innovative rainforest tracking

Rise in pancreatic cancer cases among young adults may be overdiagnosis

New study: Short-lived soda tax reinforces alternative presumptions on tax impacts on consumer behaviors

Fewer than 1 in 5 know the 988 suicide lifeline

Semaglutide eligibility across all current indications for US adults

Can podcasts create healthier habits?

Zerlasiran—A small-interfering RNA targeting lipoprotein(a)

Anti-obesity drugs, lifestyle interventions show cardiovascular benefits beyond weight loss

Oral muvalaplin for lowering of lipoprotein(a)

Revealing the hidden costs of what we eat

New therapies at Kennedy Krieger offer effective treatment for managing Tourette syndrome

American soil losing more nutrients for crops due to heavier rainstorms, study shows

With new imaging approach, ADA Forsyth scientists closely analyze microbial adhesive interactions

Global antibiotic consumption has increased by more than 21 percent since 2016

New study shows how social bonds help tool-using monkeys learn new skills

Modeling and analysis reveals technological, environmental challenges to increasing water recovery from desalination

Navy’s Airborne Scientific Development Squadron welcomes new commander

TāStation®'s analytical power used to resolve a central question about sweet taste perception

NASA awards SwRI $60 million contract to develop next-generation coronagraphs

Reducing antimicrobial resistance: accelerated efforts are needed to meet the EU targets

[Press-News.org] Aflibercept in macular oedema after BRVO: No hint of added benefit
Dossier contained no suitable data, manufacturer itself claimed no added benefit